» Articles » PMID: 31983075

Fanconi Anemia and the Underlying Causes of Genomic Instability

Overview
Date 2020 Jan 27
PMID 31983075
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Fanconi anemia (FA) is a rare genetic disorder, characterized by birth defects, progressive bone marrow failure, and a predisposition to cancer. This devastating disease is caused by germline mutations in any one of the 22 known FA genes, where the gene products are primarily responsible for the resolution of DNA interstrand cross-links (ICLs), a type of DNA damage generally formed by cytotoxic chemotherapeutic agents. However, the identity of endogenous mutagens that generate DNA ICLs remains largely elusive. In addition, whether DNA ICLs are indeed the primary cause behind FA phenotypes is still a matter of debate. Recent genetic studies suggest that naturally occurring reactive aldehydes are a primary source of DNA damage in hematopoietic stem cells, implicating that they could play a role in genome instability and FA. Emerging lines of evidence indicate that the FA pathway constitutes a general surveillance mechanism for the genome by protecting against a variety of DNA replication stresses. Therefore, understanding the DNA repair signaling that is regulated by the FA pathway, and the types of DNA lesions underlying the FA pathophysiology is crucial for the treatment of FA and FA-associated cancers. Here, we review recent advances in our understanding of the relationship between reactive aldehydes, bone marrow dysfunction, and FA biology in the context of signaling pathways triggered during FA-mediated DNA repair and maintenance of the genomic integrity. Environ. Mol. Mutagen. 2020. © 2020 Wiley Periodicals, Inc.

Citing Articles

Epithelial competition determines gene therapy potential to suppress Fanconi Anemia oral cancer risk.

Colegrove H, Monnat R, Monnat Jr R, Feder A bioRxiv. 2025; .

PMID: 40060430 PMC: 11888451. DOI: 10.1101/2025.02.26.640284.


Unraveling the Role of Ubiquitin-Conjugating Enzyme UBE2T in Tumorigenesis: A Comprehensive Review.

Gao C, Liu Y, Yu J, Wang R, Shi J, Chen R Cells. 2025; 14(1.

PMID: 39791716 PMC: 11719737. DOI: 10.3390/cells14010015.


Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).

Oliva E, Cuzzola M, Porta M, Candoni A, Salutari P, Palumbo G Int J Mol Sci. 2024; 25(21).

PMID: 39519198 PMC: 11545844. DOI: 10.3390/ijms252111646.


Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.

Fekrvand S, Abolhassani H, Esfahani Z, Fard N, Amiri M, Salehi H J Clin Immunol. 2024; 45(1):34.

PMID: 39466473 DOI: 10.1007/s10875-024-01810-w.


NuRD chromatin remodeling is required to repair exogenous DSBs in the germline.

Ananthaswamy D, Funes K, Borges T, Roques S, Fassnacht N, Jamal S bioRxiv. 2024; .

PMID: 39314477 PMC: 11419128. DOI: 10.1101/2024.09.14.613027.


References
1.
Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F . Advice on formaldehyde and glycol ethers. Lancet Oncol. 2004; 5(9):528. DOI: 10.1016/s1470-2045(04)01562-1. View

2.
Vasiliou V, Pappa A, Estey T . Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev. 2004; 36(2):279-99. DOI: 10.1081/dmr-120034001. View

3.
Ceccaldi R, Sarangi P, DAndrea A . The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol. 2016; 17(6):337-49. DOI: 10.1038/nrm.2016.48. View

4.
Gibbs-Seymour I, Oka Y, Rajendra E, Weinert B, Passmore L, Patel K . Ubiquitin-SUMO circuitry controls activated fanconi anemia ID complex dosage in response to DNA damage. Mol Cell. 2015; 57(1):150-64. PMC: 4416315. DOI: 10.1016/j.molcel.2014.12.001. View

5.
Wang A, Kim T, Wagner J, Conti B, Lach F, Huang A . A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. Mol Cell. 2015; 59(3):478-90. PMC: 4529964. DOI: 10.1016/j.molcel.2015.07.009. View